{
    "ticker": "TCRT",
    "name": "TCR2 Therapeutics Inc.",
    "description": "TCR2 Therapeutics Inc. is a clinical-stage biotechnology company focused on the development of innovative T cell therapies for the treatment of cancer. Founded in 2015, TCR2 is dedicated to harnessing the power of the immune system to create therapies that significantly improve outcomes for patients with solid tumors and hematological malignancies. The company's proprietary TRuC-T cell platform is designed to redirect T cells to target and destroy cancer cells while enhancing T cell persistence and efficacy. TCR2's lead product candidate, TC-210, is currently being evaluated in clinical trials for the treatment of patients with mesothelin-expressing tumors. With a strong commitment to advancing cell therapy and a robust pipeline of product candidates, TCR2 aims to address significant unmet medical needs in oncology. The company collaborates with leading academic institutions and industry partners to accelerate its research and development efforts, striving to bring transformative therapies to market that can improve the lives of patients battling cancer. TCR2 Therapeutics is committed to innovation, collaboration, and patient-centricity as it works towards a future where cancer can be effectively treated with bespoke immunotherapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.tcr2.com",
    "ceo": "Garrett Johnston",
    "social_media": {
        "twitter": "https://twitter.com/TCR2Therapeutics",
        "linkedin": "https://www.linkedin.com/company/tcr2-therapeutics/"
    },
    "investor_relations": "https://investors.tcr2.com",
    "key_executives": [
        {
            "name": "Garrett Johnston",
            "position": "CEO"
        },
        {
            "name": "Michael Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "T Cell Therapies",
            "products": [
                "TC-210",
                "TC-110"
            ]
        }
    ],
    "seo": {
        "meta_title": "TCR2 Therapeutics Inc. | Innovative T Cell Therapies for Cancer",
        "meta_description": "Explore TCR2 Therapeutics Inc., a biotechnology company developing cutting-edge T cell therapies to treat cancer. Learn about their innovative approaches and clinical trials.",
        "keywords": [
            "TCR2 Therapeutics",
            "T Cell Therapy",
            "Biotechnology",
            "Cancer Treatment",
            "TC-210"
        ]
    },
    "faq": [
        {
            "question": "What is TCR2 Therapeutics known for?",
            "answer": "TCR2 Therapeutics is known for developing innovative T cell therapies for the treatment of cancer."
        },
        {
            "question": "Who is the CEO of TCR2 Therapeutics?",
            "answer": "Garrett Johnston is the CEO of TCR2 Therapeutics Inc."
        },
        {
            "question": "Where is TCR2 Therapeutics headquartered?",
            "answer": "TCR2 Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are TCR2's main products?",
            "answer": "TCR2's main products include TC-210 and TC-110, both aimed at treating different types of cancer."
        },
        {
            "question": "When was TCR2 Therapeutics founded?",
            "answer": "TCR2 Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NVS",
        "BMY"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "JNJ"
    ]
}